Official Journal of the Italian Society of Orthopaedics and Traumatology
Table 2 Plasma and synovial fluid levels of soluble mediators in osteoarthritis patients and controls
Mediator | Healthy controls | Total PTOA | KL 1–2 | KL 3–4 | p |
|---|---|---|---|---|---|
Plasma | |||||
NO x (μM/L) | 15.81 (15.47 to 17.11) | 23.88 (22.17 to 29.63) | 23.88 (22.35 to 29.58)a | 24.26 (15.33 to 30.1)a | < 0.0001 |
IL-1β (pg/mL) | 0.85 (0.5 to 1.4) | 1.25 (1.0 to 1.7) | 1.4 (1.1 to 1.7)a | 1.2 (1.0 to 1.3) | 0.0185 |
IL-6 (pg/mL) | 1.29 (0.89 to 1.78) | 2.75 (1.22 to 6.0) | 3.13 (1.44 to 6.42)a | 2.22 (1.22 to 4.67)a | 0.0001 |
IL-18 (pg/mL) | 147.0 (113.0 to 209.0) | 138.17 (88.0 to 186.0) | 147.17 (88.0 to 196.0) | 113.63 (83.5 to 140.17) | 0.50 |
TNFα (pg/mL) | 2.29 (1.0 to 3.43) | 0.71 (0 to 2.43) | 0.43 (0 to 1.43) | 2.21 (0.36 to 5.93) | 0.111 |
Uric acid (μM/L) | 218.51 (196.5 to 280.03) | 344.99 (265.93 to 428.47) | 355.18 (252.6 to 439.39)a | 329.69 (280.87 to 362.35)a | 0.0017 |
Leptin (ng/mL) | 1.85 (1.26 to 8.50) | 5.81 (1.76 to 19.19) | 4.32 (1.71 to 13.13) | 12.94 (4.36 to 23.0)a | 0.0346 |
Synovial fluid | |||||
NO x (μM/L) | – | 24.23 (22.38 to 28.41) | 23.99 (22.34 to 27.29) | 26.27 (23.13 to 29.05) | 0.26 |
IL-1β (pg/mL) | – | 1.45 (1.2 to 2.0) | 1.5 (1.1 to 3.8) | 1.3 (1.2 to 1.7) | 0.60 |
IL-6 (pg/mL) | – | 3054 (346 to 6000) | 3256 (392 to 6000) | 1597.5 (300 to 6000) | 0.50 |
IL-18 (pg/mL) | – | 68.13 (54.5 to 80.0) | 67.13 (53.0 to 81.0) | 75.38 (69.13 to 77.63) | 0.42 |
TNFα (pg/mL) | – | 1.43 (0.14 to 3.14) | 1.43 (0.43 to 5.14) | 1.0 (0.07 to 2.29) | 0.34 |
Uric acid (μM/L) | – | 288.24 (218.12 to 380.0) | 289.91 (211.12 to 394.02) | 283.02 (234.28 to 361.75) | 0.99 |
Leptin (ng/mL) | – | 4.98 (3.05 to 18.75) | 4.91 (2.77 to 18.13) | 9.67 (5.0 to 22.13) | 0.18 |